GlassScriptPhysician profile
Alyssa Gregorec
NPI 1992432520
$2,559.87
in general payments reported to CMS, 2019-2025
18 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $515 · 2024: $794 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.39 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $807.20 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $396.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $351.55 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $174.68 | 2024-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $149.99 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.35 | 2023-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $115.74 | 2023-2025 | Prolastin-C Liquid |
| Amgen INC. | $98.24 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $70.91 | 2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Lilly USA, LLC | $44.50 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $32.64 | 2025 | |
| Verona Pharma, INC. | $28.40 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $25.03 | 2025 | Lumryz |
| Pfizer INC. | $21.40 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $20.59 | 2025 | Photofrin |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2023 | Glassia |
| Merck Sharp & Dohme LLC | $13.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Gregorec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.